What is the price target for RLMD stock?
9 analysts have analysed RLMD and the average price target is 9.18 USD. This implies a price increase of 48.54% is expected in the next year compared to the current price of 6.18.
RELMADA THERAPEUTICS INC (RLMD) Forecast, Price Target & Analyst Ratings
NASDAQ:RLMD • US75955J4022
Current stock price
6.18 USD
+0.27 (+4.57%)
At close:
6.18 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RELMADA THERAPEUTICS INC (RLMD).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 19, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.14
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.18
Upside
+ 48.54%
From current price of $6.18 to mean target of $9.18, Based on 9 analyst forecasts
Low
$8.08
Median
$9.18
High
$10.50
Price Target Revisions
1 Month
-10.00%
3 Months
-10.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for RLMD. The average price target is 9.18 USD. This implies a price increase of 48.54% is expected in the next year compared to the current price of 6.18.
The average price target has been revised downward by 10% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
RLMD was analyzed by 9 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about RLMD.
In the previous month the buy percentage consensus was at a similar level.
RLMD was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2026-01-23 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-12-22 | Jefferies | Initiate | Buy |
| 2025-11-19 | Mizuho | Upgrade | Neutral -> Outperform |
| 2024-12-05 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-12-04 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-09-17 | Jefferies | Upgrade | Hold -> Buy |
| 2024-06-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2023-06-15 | Mizuho | Reiterate | Buy -> Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform |
| 2022-10-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-10-14 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-13 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-09-23 | Goldman Sachs | Maintains | Buy |
| 2022-09-06 | Guggenheim | Maintains | Buy |
| 2022-05-09 | Oppenheimer | Maintains | Outperform |
| 2021-12-20 | SVB Leerink | Maintains | Outperform |
| 2021-11-18 | Mizuho | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 19, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.14
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 76.97%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-139.32%
Next Earnings Summary
RLMD is expected to report earnings on 3/19/2026. The consensus EPS estimate for the next earnings is -0.14 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 577.38% | N/A 138.33% | N/A 96.33% | N/A 41.62% | |||||||||||
| EBITDA YoY % growth | -17.09M | -16.17M 5.38% | -7.13M 55.91% | -6.92M 2.95% | -12.73M -83.96% | -60.84M -377.93% | -125.7M -106.61% | -161.25M -28.28% | N/A 34.29% | N/A 15.94% | N/A -18.54% | N/A -20.77% | N/A | N/A | N/A -14.71% | N/A 44.44% | N/A 206.15% | N/A 208.70% | N/A 65.26% | |
| EBIT YoY % growth | -17.1M | -16.22M 5.15% | -7.22M 55.49% | -6.92M 4.16% | -12.73M -83.96% | -60.84M -377.93% | -125.7M -106.61% | -161.25M -28.28% | -103.702M 35.69% | -83.891M 19.10% | N/A 40.00% | N/A -15.30% | N/A -35.33% | N/A -32.08% | N/A -19.85% | N/A 40.73% | N/A 238.11% | N/A 247.96% | N/A 55.48% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A 92.46% | N/A | N/A | N/A | N/A | -7.14 -93.19% | -5.45 23.67% | -3.28 39.82% | -2.65 19.21% | N/A 61.64% | N/A 29.43% | N/A -22.28% | N/A -13.95% | N/A -11.22% | N/A 55.96% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | -0.14 76.97% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -10.608M 44.39% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
18.62%
EPS Next 5 Year
9.59%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
-5.88%
RELMADA THERAPEUTICS INC / RLMD Forecast FAQ
What is the next earnings date for RLMD stock?
RELMADA THERAPEUTICS INC (RLMD) will report earnings on 2026-03-19, after the market close.
What are the consensus estimates for RELMADA THERAPEUTICS INC (RLMD) next earnings?
The consensus EPS estimate for the next earnings of RELMADA THERAPEUTICS INC (RLMD) is -0.14 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for RELMADA THERAPEUTICS INC stock?
The consensus rating for RELMADA THERAPEUTICS INC (RLMD) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.